The biennial TNF-family conferences have been held over the past 20 years, from the time that TNF was cloned. These meetings have followed the enormous progress in this field. Much is now known about the members of the TNF ligand and receptor families, their signaling proteins, mechanisms of action and cellular functions. This volume is the proceedings of the 12th TNF International Conference, held in April 2009. This conference focuses on the physiological, pathophysiological, and medical significance of these important regulators. Sessions at the meeting specifically address their involvement in immunity, development, apoptosis, autoimmunity, cancer, and infection, the normal function and pathology of the neuronal system, as well as major unresolved questions about their mechanisms of action.
Inhaltsverzeichnis
1;Preface by David Wallach;4 1.1; The Biennial International TNF Conferences and Their Proceedings;4 1.2; References;7 2;Preface by Marc Feldmann;8 2.1; Introduction;8 2.1.1; The TNF/TNF-R Family: A Gold Mine for Clinical Therapeutic Targets?;8 2.2; Reference;9 3;Contents;11 4;Contributors;19 5;Part I Roles of the TNF Family in Tissue Homeostasis and Normal Development;35 5.1;1 Workshop Summary: Roles of the TNF Family in Normal Development and Cancer ;36 5.2;2 TNF Conference 2009: Beyond Bones RANKL/RANK in the Immune System;38 5.2.1; The Role of the RANKLRANKOPG Axis in Bone Remodeling;38 5.2.2; RANKLRANK Signaling in the Immune System;39 5.2.2.1; Lymph Node Development;39 5.2.2.2; RANKL--RANK Signaling in T-Cell--Dendritic Cell Interactions;40 5.2.2.3; RANKL0RANK Control the Development of AIRE+ Medullary Epithelial Cells;42 5.2.2.4; RANKL--RANK Signaling in UV-Induced Immunosuppression;44 5.2.2.5; Functions of RANKL--RANK in Extramedullary Hematopoiesis and B Cells;45 5.2.3; RANKLRANK Signaling, T Cells and Bone Loss The Foundation of Osteoimmunology;46 5.2.4; RANKLRANK Are the Molecular Triggers of Bone Loss in Arthritis;47 5.2.5; RANKL Inhibition as a New Therapy to Control Bone Loss in Human Patients;50 5.2.6; Conclusions;50 5.2.7;References;51 5.3;3 The Edar Subfamily in Hair and Exocrine Gland Development;56 5.3.1; Introduction;56 5.3.2; Conservation of the Edar Subfamily;56 5.3.3; Edar Subfamily in Hair Follicle Development;57 5.3.3.1; Intricate Interplay Between Edar and Wnt Pathways Regulates Hair Development;58 5.3.3.2; Transcriptional Targets of Edar;59 5.3.3.3; Functional Redundancy Between Troy and Edar;60 5.3.4; Edar Subfamily in Glandular Appendages;61 5.3.4.1; Mammary Gland Development;62 5.3.5; Concluding Remarks;63 5.3.6;References;63 5.4;4 High Endothelial Venule Reporter Mice to Probe Regulation of Lymph Node Vasculature;67 5.4.1; Introduction;67 5.4.2; Materials and Methods;69 5.4.2.1; Mice;69 5.4.2.2; Immunization with Oxazolone;70 5.4.2.3;
Development of HEC6ST-GFP Reporter Mice;70 5.4.2.4; Immunofluorescence Analysis;71 5.4.3; Results and Discussion;71 5.4.3.1; Vessels Positive for Markers of both HEVs and LVs Are Apparent After Immunization;71 5.4.3.2; HEC6ST-eGFP Mice Have Been Developed;72 5.4.3.3; HEC6ST-eGFP Mice Recapitulate Endogenous HEC6ST Expression;74 5.4.4;References;75 5.5;5 Eiger and Wengen: The Drosophila Orthologs of TNF/TNFR;77 5.5.1; Identification and Signaling Mechanisms of Eiger;77 5.5.2; Role of Eiger in Epithelial Tumor Suppression;78 5.5.3; Other Physiological Roles of Eiger;80 5.5.3.1; Roles in Host Defense;80 5.5.3.2; Role in Cell Proliferation;81 5.5.3.3; Role in Pain Sensitization;81 5.5.4; Further Genetic Analysis of Eiger Signaling;81 5.5.5;References;81 6;Part II Novel Aspects of Signaling Activation by the TNF Family: Novel Aspects of the Functions of the TRAFs and cIAPs;83 6.1;6 Workshop Summary: Novel Aspects of the Functions of the TRAFs and cIAPs ;84 6.1.1;References;90 6.2;7 TRAF2 and Cellular IAPs: A Critical Link in TNFR Family Signaling;93 6.2.1; Discovery of Cellular IAP Proteins and TRAF2;93 6.2.2; Structural Properties of Cellular IAPs and TRAF2;93 6.2.3; TRAF2 and c-IAP Proteins in Signaling Pathways;96 6.2.4; Regulation of Apoptotic Pathways by c-IAPs and TRAF2;99 6.2.5;Targeting c-IAPs and TRAF2 for Therapeutic Intervention ;101 6.2.6;References;103 6.3;8 New Perspectives in TNF-R1-Induced NF-B Signaling;109 6.3.1; TNF-R1-Induced Activation of Canonical NF-B;109 6.3.2; cIAP1/2 Are Required for RIPK1 Ubiquitylation and NF-B Activation;111 6.3.3; RIPK1 Is Not Required for NF-B Activation;113 6.3.4; Alternative Mechanisms for NF-B Activation;114 6.3.5; NF-B and TNF-Mediated Cell Death;115 6.3.6;References;116 6.4;9 Structural Studies of NEMO and TRAF6: Implications in NF-B Activation;119 6.4.1;References;120 7;Part III Novel Aspects of Signaling Activation by the TNF: Ubiquitin Modification of Signaling Proteins;122 7.1;10 Modification by Single Ubiquitin Mo
ieties Rather Than Polyubiquitination Is Sufficient for Proteasomal Processing of the p105 NF-B Precursor;123 7.1.1; Introduction;123 7.1.2; Results;125 7.1.2.1; Involvement of the Ubiquitin System in Processing of p105;125 7.1.2.2; Processing of p105 Does Not Require Polyubiquitination;125 7.1.2.3; Monoubiquitination(s) Is Sufficient for Processing of p105 In Vivo;128 7.1.2.4; Processing of p105 Requires Multiple Monoubiquitinations;131 7.1.2.5; The 26S Proteasome Binds Multiply Monoubiquitinated p105;131 7.1.3; Discussion;131 7.1.4;References;134 7.2;11 Selective Binding of Linear Ubiquitin Chains to NEMO in NF-kappaB Activation;135 7.2.1; Introduction;135 7.2.2; Main Text;136 7.2.2.1; The NEMO--UBAN Domain Selectively Binds to Linear Ubiquitin Chains;136 7.2.2.2; The NEMO--UBAN Domain Forms a-Helical Dimer;137 7.2.2.3; Determination of Linear-Ubiquitin Binding Surfaces in the NEMO--UBAN Domain;137 7.2.2.4; Role of Linear Ubiquitin Binding to NEMO in Regulation of Signaling;137 7.2.3; Discussion and Future Perspectives;139 7.2.4;References;141 7.3;12 The Linear Ubiquitin Chain Assembly Complex (LUBAC) Forms Part of the TNF-R1 Signalling Complex and Is Required for Effective TNF-Induced Gene Induction and Prevents TNF-Induced Apoptosis;143 7.3.1; Introduction;143 7.3.2; Identification of HOIL-1 and HOIP as Novel Components of the Native TNF-RSC;145 7.3.3; LUBAC Recruitment to the TNF-RSC Is Dependent on TRADD, TRAF2/5, and cIAP1/2;145 7.3.4; HOIL-1 and HOIP Directly Interact with Specific Polyubiquitin Chains;146 7.3.5; HOIL-1 and HOIP Mediate TNF-Induced Signalling Events, Gene Induction, and Protect from TNF-Induced Apoptosis;147 7.3.6; HOIL-1 and HOIP Are Required for Stable TNF-RSC Formation;147 7.3.7; Conclusions;148 7.3.8;References;152 7.4;13 Temporal Control of TNF Signaling by Miz1;155 7.4.1;References;156 8;Part IV Novel aspects of Signaling Activation by the TNF Family: TNF Signaling and Gene Regulatory Networks;157 8.1;14 Large-Scale RNAi Screens to Dis
sect TNF and NF-B Signaling Pathways;158 8.1.1; Introduction;158 8.1.2; TNF-Induced NF-B Activation;159 8.1.3; TNF/NF-B Signaling: A Link Between Inflammation and Cancer;161 8.1.4; RNAi Screens to Dissect Signaling Pathways;162 8.1.5; Design Principles of Large-Scale RNAi Screens for TNF/NF-B;162 8.1.6; New Targets, New Drugs?;164 8.1.7;References;165 8.2;15 Pathogenic Role of IL-6 Combined with TNF- or IL-1 in the Induction of Acute Phase Proteins SAA and CRP in Chronic Inflammatory Diseases;167 8.2.1; Introduction;167 8.2.2; Contribution of Cytokines to the Pathogenesis of RA;167 8.2.2.1; In Vitro SAA Induction Mechanism;168 8.2.3; In Vitro CRP Induction Mechanism;171 8.2.4; Inhibition of SAA and CRP Production by IL-6 Blockade Both In Vitro and In Vivo;172 8.2.5; Pathogenic Role of IL-6 Combined with TNF- or IL-1 on the Induction of SAA and CRP in RA Based on Evidence Obtained from In Vitro Experiments;174 8.2.6;References;175 8.3;16 Understanding Life and Death at CD95;177 8.3.1; Introduction;177 8.3.2; Results and Discussion;180 8.3.3; Materials and Methods;184 8.3.3.1; Cell Lines;184 8.3.3.2; Antibodies and Reagents;184 8.3.3.3; Analysis of Total Cellular Lysates;185 8.3.3.4; NF-B Activation Assay;185 8.3.3.5; Cell Death Assay;185 8.3.4;References;186 8.4;17 Unique Personalities Within the NF-B Family: Distinct Functions for p65 and RelB in the Osteoclast;188 8.4.1; Distinct Kinetics for Activation of p65 and RelB in the OC Lineage;189 8.4.2; Role of p65 in OC Apoptosis;189 8.4.3; Role of RelB in OC Differentiation;190 8.4.4; cRel Is Not Required for Osteoclastogenesis;190 8.4.5; Summary;191 8.4.6;References;192 9;Part V Roles of the TNF Family in Infectious Diseases and Interrelationship of the TNF Family and Pattern Recognition Receptor Signaling: Roles of the TNF Family in Infectious Diseases;193 9.1;18 Workshop Summary: Functions of the TNF Family in Infectious Disease;194 9.1.1; The Role of Soluble TNF, Membrane TNF, and Lymphotoxin in Mycobacterium tuber
culosis Infection;194 9.1.2; Interplay Between Heme and TNF in Severe Malaria;195 9.1.3; TNF in Chagas Disease;195 9.1.4; Subversion of TNF-Mediated Viral Control by Poxviruses;195 9.1.5; 4-1BB/4-1BBL in Influenza and HIV Infections;196 9.1.6; A Lymphotoxin Pathway to Hepatocellular Carcinoma;196 9.1.7; Emerging Themes;197 9.1.8;References;197 9.2;19 Role of 4-1BBL and TRAF1 in the CD8 T Cell Response to Influenza Virus and HIV;199 9.2.1; Introduction;199 9.2.2; Role of TRAF1 in 4-1BB Signaling;199 9.2.3; How Unique Are 4-1BB-Induced Survival Signals?;201 9.2.4; Role of 4-1BBL and TRAF1 in Restoring Function in CD8 T Cells from Chronically HIV Infected Individuals;201 9.2.5; Role of 4-1BBL in Mild Versus Severe Influenza Virus Infection;202 9.2.6; Role of 4-1BBL and TRAF1 in T Cell Memory;203 9.2.7; A Model for the Maintenance of CD8 T Cell Memory;204 9.2.8; Concluding Remarks;205 9.2.9;References;205 9.3;20 Roles of Soluble and Membrane TNF and Related Ligands in Mycobacterial Infections: Effects of Selective and Non-selective TNF Inhibitors During Infection;209 9.3.1; Introduction;209 9.3.2; Roles of TNF in Mycobacterial Infections;210 9.3.3; Soluble TNF, Membrane-Bound TNF, and Lymphotoxins;210 9.3.4; Role of TNF in Experimental Animal Models of Tuberculosis Infection;212 9.3.5; Membrane TNF Protects from BCG and Acute Tuberculosis Infections;213 9.3.6; Lymphotoxins and LIGHT in Immunity to Mycobacterial Infections;214 9.3.7; Neutralization of TNF and Risks of New Infection and Reactivation of Latent Tuberculosis;214 9.3.8; Strategies to Block TNF Activities;215 9.3.9; TNF and Chemokines in Mycobacterial Infections;217 9.3.10; Conclusion;217 9.3.11;References;218 9.4;21 Poxviral TNFRs: Properties and Role in Viral Pathogenesis;224 9.4.1; Poxviruses;224 9.4.2; Poxviral TNF-Binding Proteins;224 9.4.3; vTNFRs in Pathogenesis;227 9.4.4; Ectromelia Virus;227 9.4.5; Conclusions;229 9.4.6;References;229 9.5;22 Heme Sensitization to TNF-Mediated Programmed Cell Death;232
9.5.1; Introduction;232 9.5.2; Malaria;233 9.5.3; A Central Role of Free Heme in the Pathogenesis of Severe Malaria;234 9.5.4; Free Heme Sensitizes Cells to Undergo TNF-Mediated Apoptosis;236 9.5.5; Concluding Remarks;237 9.5.6;References;238 9.6;23 TNF- and TNFR in Chagas Disease: From Protective Immunity to Pathogenesis of Chronic Cardiomyopathy;241 9.6.1; Introduction;241 9.6.2; TNF- Polymorphisms in Chagas Disease;242 9.6.3;TNF- in Trypanosoma cruzi Immunity;243 9.6.4;Beneficial Effects of TNF- Blockade in Trypanosoma cruzi Infection;244 9.6.5; Conclusions and Future Avenues;246 9.6.6;References;247 9.7;24 Lymphotoxins Link to Carcinogenesis: Friend or Foe? From Lymphoid Neogenesis to Hepatocellular Carcinoma and Prostate Cancer;251 9.7.1; Lymphotoxin: Past and Present;251 9.7.2; From Toxicity to Function;251 9.7.3; Lymphotoxin, Lymphoid Neogenesis, and Lymphoid Microarchitecture;252 9.7.4; Lymphotoxin and Inflammation;253 9.7.5; LTR Signaling in Health and Disease;255 9.7.6; NFB, Chronic Inflammation, and Cancer;255 9.7.7; Lymphotoxin and Its Link to Cancer;257 9.7.8; LTR Signaling in the Liver;258 9.7.9; Hepatic LTR Signaling and Hepatocellular Carcinoma;258 9.7.10;References;264 10;Part VI Roles of the TNF Family in Infectious Diseases and Interrelationship of the TNF Family and Pattern Recognition Receptor Signaling: Interrelationship of the TNF Family and Pattern Recognition Receptor Signaling;270 10.1;25 Anti-inflammatory Functions of Caspase-8;271 10.1.1; Involvement of Signaling Proteins Activated by TNF/NGF Family Members in Signaling Pathways Activated by Other Inducers;271 10.1.2; Inflammatory Processes Triggered by Caspase-8 Deficiency;272 10.1.3; Exploring the Mechanism for a Skin Inflammatory Disease Prompted by Caspase-8 Deficiency in the Epidermis Revealed an Inhibitory Effect of Caspase-8 on Signaling for IRF3 Activation;274 10.1.4; Regulation of RIG-I Signaling by Caspase-8;277 10.1.5; Epilogue;277 10.1.6;References;278 10.2;26 Endogenous Liga
nd-Induced Activation of TLR4 in Pre-metastatic Phase Is Both Downstream and Upstream of TNF Signaling;279 10.2.1; Discovery of Endogenous Ligands for TLR4 in Pre-metastatic Milieu;279 10.2.2; The Complex Paracrine Modes in TNFR and TLR4 Crosstalks;281 10.2.3; Conclusion;283 10.2.4;References;284 11;Part VII Novel Aspects of Immune Regulation by the TNF Family;287 11.1;27 Introductory Words About TL1A/DR3;288 11.1.1;References;290 11.2;28 Introductory Words About TWEAK/Fn14;292 11.2.1;References;294 11.3;29 Insights into TL1A and IBD Pathogenesis;295 11.3.1; Introduction;295 11.3.2;TL1A (TNFSF15) Is an IBD Severity Associated Gene ;296 11.3.3; Upstream Regulators of the TL1A-DR3 Signaling Pathway;297 11.3.4; Downstream Effects of the TL1A-DR3 Signaling Pathway;300 11.3.5; Role of TL1A in Inflammatory Diseases;301 11.3.6; Conclusion;302 11.3.7;References;302 11.4;30 The Role of TNFRSF25:TNFSF15 in Disease and Health?;305 11.4.1; Introduction;305 11.4.2; Structure, Expression and Signaling;306 11.4.3; TL1A:TNFR25 in T Cell Function;308 11.4.4; TL1A:TNFR25 in Auto-aggressive Disease;309 11.4.5; TL1A:TNFR25 in Health?;311 11.4.6;References;311 11.5;31 Identification of New Candidates as Mucosal Vaccine Adjuvant in TNF Family Cytokines;315 11.5.1; Mucosal Immunity and Vaccine;315 11.5.2; Identification of New Candidate Mucosal Vaccine Adjuvants Among TNF Superfamily Cytokines;316 11.5.3; Concluding Remarks;319 11.5.4;References;320 11.6;32 The TWEAK/Fn14 Pathway in Tissue Remodeling: For Better or for Worse;321 11.6.1; Introduction;321 11.6.2; TWEAK;323 11.6.3; Fn14;323 11.6.4; Fn14 Signaling;324 11.6.5; Role of TWEAK/Fn14 Pathway in Disease;326 11.6.6; Role of TWEAK/Fn14 in Intestinal Inflammation and Injury;332 11.6.7; Summary and Perspective;335 11.6.8;References;336 11.7;33 TWEAK and the Kidney: the Dual Role of a Multifunctional Cytokine;339 11.7.1; Introduction;339 11.7.2; TWEAK and Fn14 Expression in Renal Cells;340 11.7.3; TWEAK Biological Activity in the Kidney;
341 11.7.3.1; Pro-inflammatory Effect of TWEAK in the Kidney;341 11.7.3.2; TWEAK and Renal Cell Death;341 11.7.3.3; TWEAK and Renal Cell Proliferation;342 11.7.4; TWEAK and Fn14 in Experimental Kidney Disease;343 11.7.4.1; Acute Kidney Injury;343 11.7.4.2; Non-inflammatory Renal Regeneration Model: Uninephrectomy;345 11.7.4.3; Autoimmune Kidney Disease: Lupus Nephritis;346 11.7.5; Future Lines of Research;346 11.7.6;References;347 11.8;34 TWEAK and TNF Regulation of Sclerostin: A Novel Pathway for the Regulation of Bone Remodelling;352 11.8.1; Introduction;352 11.8.2; TWEAK;352 11.8.3; A Role for TNF Family Members in Bone Remodeling;353 11.8.4; Human Osteoblasts and Osteoblast-Like Cell Lines Express Fn14 and TWEAK;353 11.8.5; TWEAK Inhibits In Vitro Mineralisation and Antagonizes the Osteogenic Effect of TNF;353 11.8.6; Effect of TWEAK and TNF on Osteoblast Proliferation;354 11.8.7; Effect of TWEAK and TNF on Osteoblast Osteogenic Gene Transcription;355 11.8.8; Interaction Between TWEAK and TNF;357 11.8.9; The Wnt Signalling Pathway and Inhibitors: Sclerostin;357 11.8.10; TWEAK Alone and in Combination with TNF Induce Sclerostin Expression;357 11.8.11; Concluding Remarks;358 11.8.12;References;360 12;Part VIII Control of Lymphocyte Function and Repertoire by the TNF Family;364 12.1;35 Workshop Summary: Control of Lymphocyte Function and Repertoire by the TNF Superfamily;365 12.2;36 The Canonical and Unconventional Ligands of the Herpesvirus Entry Mediator;367 12.2.1; Introduction;367 12.2.2; Canonical Ligands: LIGHT and LT;369 12.2.3; Unconventional Ligands: BTLA and CD160;370 12.2.4; Distinct Ligand Binding Sites on HVEM;371 12.2.5; Viral Ligands of HVEM and BTLA: HSV gD and UL144;371 12.2.6; The Trans and Cis of HVEM Signaling;372 12.2.7;References;373 12.3;37 The Lymphotoxin Pathway as a Novel Regulator of Dendritic Cell Function;377 12.3.1;References;384 12.4;38 Involvement of the Cytokine Receptor CD137 in Murine Hematopoiesis;389 12.4.1; Introduction;389 12.
4.2; Effects of CD137 on Murine Hematopoietic Progenitor Cells;390 12.4.2.1; CD137 and Its Ligand Are Expressed in the Bone Marrow;390 12.4.2.2; CD137 Induces Proliferation and Colony Formation of Hematopoietic Progenitor Cells;390 12.4.2.3; CD137 Induces Cell Differentiation Toward Macrophages;392 12.4.3; Other Activities of CD137 in Hematopoiesis;393 12.4.4; Conclusion;394 12.4.5;References;395 12.5;39 LTBR-Pathway in Sjogrens Syndrome: CXCL13 Levels and B-cell-Enriched Ectopic Lymphoid Aggregates in NOD Mouse Lacrimal Glands Are Dependent on LTBR;397 12.5.1; The TNF Family and Inflammatory Versus Homeostatic Pathways;397 12.5.2; Ectopic Lymphoid Tissue Development and Homeostasis in Disease;397 12.5.3; What Is the Role of Ectopic Follicles in Disease;398 12.5.4; Clinical Utility of Dispersing Ectopic Follicles in Sjogrens Syndrome;398 12.5.5; Role of LTBR in Lymphocytic Infiltrates in Lacrimal Glands;399 12.5.6; Involvement of the LTBR Axis in Lacrimal Gland Pathology;400 12.5.7; Affymetrix Chip Analysis Implication of LTBR Pathway and Chemokine CXCL13;400 12.5.8; CXCL13 Production in Lacrimal Glands Lacking FDC Networks;402 12.5.9;References;403 12.6;40 MEK Kinase 1: Kinase Domain Deficiency in Mice Reveals a Role in Orchestrating the Thymus-Dependent Immunity and TNFR Family Signaling;405 12.6.1; Introduction;405 12.6.2; Activation of E3 Ub Ligase Itch by the T-Cell Receptor;406 12.6.3; Thymus-Dependent Immune Responses and TNFR Signaling in B Cells;407 12.6.4; Two-Stage Cytokine Receptor Signaling;408 12.6.5; Perspectives;409 12.6.6;References;410 13;Part IX Advances in Applying Our Knowledge to Therapy: Mechanisms of Pathological and Therapeutic Effects of the TNF Family ;412 13.1;41 Introduction to the Session Mechanisms of Pathological and Therapeutic Effects of the TNF Family;413 13.2;42 Mechanisms Regulating TNF-Driven Gut and Joint Inflammation;415 13.2.1; The Gut Joint Axis in Spondyloarthritis;415 13.2.2; Modeling Spondyloarthritis in Mice: Which Cells
Are Targets of Pathogenic TNF?;416 13.2.3; NKT Cells: Regulators or Effectors in Arthritic Disease?;417 13.2.4;References;419 13.3;43 Lessons from Anti-TNF Biologics: Infliximab Failure in a TRAPS Family with the T50M Mutation in TNFRSF1A;421 13.3.1; Assessment of the Effect of Anti-TNF Biologicals in an Irish Family with the T50M Variant of TNFRSF1A;422 13.3.2; Therapeutic Options in the Treatment of TRAPS: A Revised View;425 13.3.3; Conclusion;428 13.3.4;References;429 13.4;44 Modalities of Experimental TNF Blockade In Vivo: Mouse Models;432 13.4.1; Introduction;432 13.4.2; Results and Discussion;433 13.4.2.1; Novel Humanized Mice for Studying TNF Inhibition In Vivo;433 13.4.2.2; Mouse Models to Evaluate Functions of TNF Produced by Distinct Cell Types or in Distinct Molecular Forms (or Both);436 13.4.2.3; Distinct Functions of TNF Produced by Individual Types of Immunocytes in Disease;436 13.4.2.4; Effects of Non-conventional TNF Blockers on Acute Septic Shock and on the Structure of Secondary Lymphoid Organs;439 13.4.3;References;440 13.5;45 Tumor Necrosis Factor- Signaling via TNFR1/p55 Is Deleterious Whereas TNFR2/p75 Signaling Is Protective in Adult Infarct Myocardium;443 13.5.1; Background;443 13.5.1.1; Aging and Angiogenesis;443 13.5.1.2; TNF, TNF Receptors, and Angiogenesis;443 13.5.1.3; Aging, TNF Signaling, and Post-ischemic Recovery;444 13.5.2; Results;445 13.5.2.1; Constitutive Expression of p75 Is Decreased in Human PB EPCs from Donors of Increasing Age;445 13.5.2.2; Post-AMI Survival and Functional Myocardial Recovery Is Impaired in Old p75KO Mice;445 13.5.2.3; Cardiac Troponin I (cTnI) Expression Is Increased in Infarct Border Zone in p75KO Mice;448 13.5.2.4; Capillary Density Is Decreased in Infarct and Infarct Border Zone in Old WT and Young and Old p75KO Mice;449 13.5.2.5; Compared to Old WT Mice Post-AMI Functional Capillary Density Is Decreased in Old p75KOs in Infarct Border Zone;449 13.5.2.6; Ischemia-Induced Apoptosis Is Increased in the My
ocardium of Old p75KO Mice 28 Days Post-AMI;451 13.5.2.7; Expression of Several Angiogenic Growth and Stem Cell-Derived Factors and Their Receptors Is Decreased in Peripheral Blood EPCs from Adult Donors;451 13.5.3; Summary;454 13.5.4;References;456 13.6;46 TNF- Regulation of CD38 Expression in Human Airway Smooth Muscle: Role of MAP Kinases and NF-B;459 13.6.1; Introduction;459 13.6.2; CD38/cADPR Signaling Pathway;459 13.6.3; Regulation of CD38 Expression in ASM Cells;461 13.6.3.1; Cd38 Gene and Promoter;461 13.6.3.2; Cytokine Regulation of CD38 Expression;463 13.6.4; TNF- and CD38 Expression;463 13.6.4.1; TNF-;463 13.6.4.2; TNF- Signaling and MAP Kinases;464 13.6.5; Concluding Remarks;466 13.6.6;References;466 13.7;47 Functional Consequences of Disease-Associated Mutations in TNFR1 Elucidated by Transcriptome Analysis;470 13.7.1; Introduction;470 13.7.2; TNFR1 Mutations and TRAPS;471 13.7.3; Clinical Features;472 13.7.4; Dissecting the Molecular Pathogenesis of TRAPS;472 13.7.5; Altered Gene Expression Profile in Cells Expressing TNFR1 TRAPS Mutants;474 13.7.6;References;476 13.8;48 Tumor Necrosis Factor- and Kidney Function: Experimental Findings in Mice;480 13.8.1;Direct Effects of TNF- on Renal Hemodynamics and Excretory Function ;481 13.8.2;What Would Be the Mechanism (s) of These Renal Actions TNF-?;481 13.8.3;What Would Be the Mechanism of Natriuresis Induced by TNF- ? ;483 13.8.4; Renal mRNA Expression of Oxidative and Nitrosative Enzymes in Response to TNF Infusion;485 13.8.5; Conclusion;486 13.8.6;References;487 13.9;49 Strategies to Inhibit the Toxicity of Systemic TNF Treatment;490 13.9.1; Introduction;490 13.9.2; Inhibition of Matrix Metalloproteinases;491 13.9.3; Induction of HSP70;491 13.9.4; Inhibition of Cytokines;492 13.9.5; Conclusion;492 13.9.6;References;492 14;Part X Advances in Applying our Knowledge to Therapy: Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family;494 14.1;50 Workshop Summary: Introduction to
Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family;495 14.1.1;References;498 14.2;51 Anti-inflammatory Effects of a Novel TNFR1-Selective Antagonistic TNF Mutant on Established Murine Collagen-Induced Arthritis;500 14.2.1; Anti-TNF Therapy for Autoimmune Diseases;500 14.2.2; Creating Functional Mutants with Advanced Medical Applications;501 14.2.3; Bioconjugation as a Polymeric DDS;503 14.2.4; Conclusion Remarks;505 14.2.5;References;505 14.3;52 A Proliferation-Inducing Ligand (APRIL): The Development of Antagonistic Agents as Potential Therapeutics and Deciphering the Role of Heparan Sulphate Proteoglycans (HSPGs) in APRIL Signalling;508 14.3.1; Introduction;508 14.3.2; The Development and Characterisation of Antagonistic Monoclonal Antibodies Against Human APRIL;509 14.3.3; The Role of HSPGs in APRIL Signalling;510 14.4;References;512 14.5;53 Genetic Engineering of Death Ligands for Improvement of Therapeutic Activity;514 14.5.1; Introduction;514 14.5.2; Stabilization of Trimer Formation;516 14.5.3; Conversion of Inactive Death Ligands into Highly Active Molecules Through Tumor-Directed Targeting;517 14.5.4; Targeting-Dependent Enhancement of TRAILs Antitumoral Activity;518 14.5.5; Exploiting Therapeutic Potential of CD95L- and TNF-Based Reagents: Targeted Activation and Prodrugs;520 14.5.6; Bifunctional Death Ligand Fusion Proteins;523 14.5.7; Conclusion;524 14.5.8;References;525 14.6;54 Computational Design of TNF Ligand-Based Protein Therapeutics;527 14.6.1; Concluding Remarks;535 14.6.2;References;536 15;Part XI Roles of the TNF Family in Neuronal Development, Function, and Pathology;541 15.1;55 Workshop Summary: Roles of the TNF Family in Neuronal Development, Function and Pathology;542 15.2;56 TNF: A Key Neuroinflammatory Mediator of Neurotoxicity and Neurodegeneration in Models of Parkinson's Disease;544 15.2.1;References;545 15.3;57 The Contribution of TNF to Synaptic Plasticity and Nervous System Function;546 15.3.1;Refe
rences;558 15.4;58 Intracellular and Intercellular Cross Talk Between NGF and TNF;563 15.4.1; Introduction;563 15.4.2;TNF Signalling Through TNFR2 Modulates NGF Signalling ;563 15.4.3;NGF Appears to Change the Effects of Endogenous TNF on Neuronal Survival;564 15.4.4;Possible Contributions of Endogenous TNF to Tumourigenesis of Neuroblastomas ;565 15.4.5; Where Is the Endogenous Source of NGF in the Adult Nervous System?;565 15.4.6;A Possible Intercellular Loop of NGF and TNF Expression ;566 15.4.7; Conclusion;566 15.4.8;References;567 15.5;59 TNFR2 Target for Therapeutics Against Neurodegenerative Diseases?;570 15.5.1; TNF and Its Receptors;570 15.5.2; TNF and TNFRs in Neurodegenerative Disease;570 15.5.3; TNF and SK Channels;573 15.5.4; Statins and the TNFR2 Neuroprotective Pathway;574 15.5.5; Overall Discussion and Conclusion with Future Perspectives;575 15.5.6;References;575 15.6;60 A Role for Neuronal NF-B in Suppressing Neuroinflammation and Promoting Neuroprotection in the CNS;577 15.6.1; Introduction;577 15.6.2; Transcription Factor NF-B in EAE Pathology;577 15.6.3; Conditional Gene Targeting of IKK Kinase During Autoimmune, Demyelinating Disease;578 15.6.4; Proinflammatory and Neuroprotective Effects During EAE in nIKKKO Mice;580 15.6.5; Conclusion;582 15.6.6;References;582 16;Part XII Cell Death Mechanisms Controlled by the TNF Family;584 16.1;61 Workshop Summary: Cell Death Mechanisms Controlled by the TNF Family;585 16.1.1; Introduction;585 16.2;62 A RNA Interference Screen Identifies RIP3 as an Essential Inducer of TNF-Induced Programmed Necrosis;589 16.2.1; Introduction;589 16.2.2; Identification of RIP Kinases as Critical Mediators for Programmed Necrosis;589 16.2.3; RIP3 Is Recruited to the Cytoplasmic Signaling Complex and Interacts with RIP1 via the RHIM;590 16.2.4; The RHIM and Kinase Domains of RIP1 and RIP3 Are Essential for Programmed Necrosis;590 16.2.5; RIP3 Controls ROS Production;591 16.2.6; The Role of RIP3 in T-Cell Death;591 16.2.7; RIP3
Participates in Anti-viral Innate Immune Responses;592 16.2.8;References;593 16.3;63 The Extracellular Matrix Protein CCN1 Dictates TNF and FasL Cytotoxicity In Vivo;594 16.3.1; Introduction;594 16.3.2; The CCN Family of Extracellular Matrix Proteins;594 16.3.3; CCN Proteins and TNF Cytokines Synergize to Induce Apoptosis In Vitro and In Vivo;595 16.3.4; ROS Mediates Signaling Cross Talk Between CCNs and TNF or FasL;598 16.3.5; Future Prospects;599 16.3.6;References;599 16.4;64 Compartmentalization of TNF-Receptor 1 Signaling: TNF-R1-Associated Caspase-8 Mediates Activation of Acid Sphingomyelinase in Late Endosomes;603 16.4.1; TNF-Receptor Signaling;603 16.4.2; Non-apoptotic Signaling of TNF-Receptor 1;603 16.4.3; Apoptosis-Inducing Signals from TNF-Receptor 1;604 16.4.4; Mechanisms of Receptor Internalization;604 16.4.5; DISC Assembly Occurs on Internalized TNF-Receptosomes;605 16.4.6; A-SMase Activation by TNF;608 16.4.7; Caspase-8 Deficiency Prevents TNF Activation of A-SMase and Cathepsin D;609 16.4.8; Active Caspase-8 Colocalizes with Internalized TNF-Receptosomes and A-SMase;609 16.4.9; Proteolytic Cleavage of Pro-A-SMase Correlates with Enhanced Enzymatic Activity;610 16.4.10;References;611 16.5;65 TNF/TNF Receptor 1-Mediated Apoptosis in Hepatocytes;615 16.5.1; Introduction;615 16.5.2; The Biology of TNF and TNF Receptor 1 System in the Liver;616 16.5.3; The Signaling and Function of TNF Receptor 1 in the Liver;617 16.5.4; Other Unique Observations on TNFR1 in Hepatocytes;619 16.5.5;References;620 16.6;66 Regulation of Cell Death by c-FLIP Phosphorylation;623 16.6.1; Introduction;623 16.6.2; Activation of Apoptosis by Death Receptors;623 16.6.3; c-FLIP as a Regulator of the Cell Fate;624 16.6.4; Regulation of c-FLIP by Post-Translational Modifications;625 16.6.5; PKC-Mediated Phosphorylation Regulates the Stability of the Short c-FLIP Isoforms;626 16.6.6; Pursuing Interest on c-FLIP Ubiquitylation;627 16.6.7;References;627 17;Appendix I: Contributors to Ab
stracts of Talks and Posters at the 12th TNF Conference;629 18;Appendix II: Abstracts of Talks and Posters Presented at the 12th TNF Conference;640 18.1; KEYNOTE LECTURE;640 18.1.1; ORCHESTRATION OF THE TNF RESPONSE BY MESSENGER RNA STABILITY AND MICRORNAS;640 18.2; LECTURES ROLES OF THE TNF FAMILY IN TISSUE HOMEOSTASIS AND NORMAL DEVELOPMENT;641 18.2.1; BEYOND BONES - THE MULTIPLE FUNCTIONS OF RANKL-RANK;641 18.2.2; HAIR FOLLICLE RANK-LIGAND REGULATES EPITHELIAL GROWTH VIA BCL-3;641 18.2.3; TNFs IN HAIR AND MAMMARY GLAND DEVELOPMENT;642 18.2.4; TNF PRIMES ENDOTHELIAL CELLS FOR ANGIOGENIC SPROUTING BY INDUCING A TIP CELL PHENOTYPE;643 18.2.5; LTalpha CONTRIBUTES TO LYMPHATIC VESSEL DEVELOPMENT AND FUNCTION;643 18.2.6; TNF SIGNALING AND ITS PHYSIOLOGICAL ROLES IN DROSOPHILA;644 18.3; ROLES OF THE TNF FAMILY IN CANCER;644 18.3.1; THE EGFR PATHWAY: RECENT LESSONS IN SIGNAL TRANSDUCTION;644 18.3.2; STUDY OF APRIL EXPRESSION AND APRIL-MEDIATED SIGNALING IN BREAST CANCER;645 18.3.3; ROLE OF RECEPTOR ACTIVATOR OF NF-B LIGAND (RANKL) IN TUMORIGENESIS AND METASTASIS;646 18.3.4; TNF-MEDIATED MYELOID CELLS SURVIVAL IS NECESSARY FOR TUMOR GROWTH;648 18.3.5; FAS SIGNAL PROMOTES LUNG CANCER GROWTH BY RECRUITING MYELOID-DERIVED SUPPRESSOR CELLS VIA CANCER CELL-DERIVED PGE2;648 18.3.6; NF-KAPPAB INHIBITION AND SKIN CANCER: A VISCOUS CIRCLE OF CHRONIC INFLAMMATION AND IMMUNOSUPPRESSION DRIVEN BY TNFR1 IN KERTINOCYTES;649 18.3.7; ENDOGENOUS LIGAND-INDUCED ACTIVATION OF TLR4 IN PRE-METASTATIC PHASE IS BOTH DOWNSTREAM AND UPSTREAM OF TNF SIGNALING;650 18.3.8; MECHANISMS OF THE TUMOR-PROMOTING ACTION OF TNF- IN EPITHELIAL TUMORS;650 18.4; NOVEL ASPECTS OF SIGNALING ACTIVATION BY THE TNF FAMILY;651 18.4.1; NON-CANONICAL MODES OF UBIQUITINATION IN REGULATION OF TRANSCRIPTION: PROCESSING OF THE NF- B p105 AND ACTIVATION OF POLYCOMB REPRESSIVE COMPLEX 1;651 18.4.2; SIGNALING LESSONS FROM DEATH RECEPTORS;652 18.4.3; IN VIVO STUDY OF THE (PATHO)PHYSIOLOGICAL ROLE OF THE ANTI-APOPTOTIC AND ANT
I-INFLAMMATORY PROTEIN A20, USING GENETICALLY MODIFIED MICE;653 18.4.4; REGULATION OF TNF-INDUCED JNK ACTIVATION AND INFLAMMATION BY SMOR1;654 18.4.5; CULLIN3-BASED POLYUBIQUITINATION AND P62-DEPENDENT AGGREGATION OF CASPASE-8 MEDIATE CELL EXTRINSIC APOPTOSIS SIGNALING;654 18.4.6; SELECTIVE BINDING OF LINEAR UBIQUITIN CHAINS TO NEMO (NF-B ESSENTIAL MODULATOR) IN NF-B ACTIVATION;655 18.4.7; A NOVEL UBIQUITIN LIGASE RECRUITED TO THE TNF-R1 SIGNALLING COMPLEX IS REQUIRED FOR EFFICIENT TNF-INDUCED NF-B ACTIVATION AND GENE INDUCTION;656 18.5; TRANSCRIPTIONAL NETWORKS AND SYSTEMS BIOLOGY;657 18.5.1; CHARACTERIZATION OF NOVEL TNF/NF-B SIGNALING PATHWAY COMPONENTS BY GENOME-WIDE RNAI;657 18.5.2; RNA-INTERFERENCE BASED SCREEN IDENTIFIES NEW FACTORS IMPORTANT FOR NF-kappaB ACTIVATION AND TERMINATION;657 18.5.3; CASEIN KINASE 1, NF-B, AND HUMAN LYMPHOMA CELL SURVIVAL;658 18.5.4; PATHOGENIC ROLE OF IL-6 WITH TNF- or IL-1 ON THE INDUCTION OF ACUTE PHASE PROTEINS IN CHRONIC INFLAMMATORY STATUS OF AUTOIMMUNE DISEASE;659 18.5.5; NEW INSIGHTS IN LTBR-MEDIATED NF-B ACTIVATION;659 18.5.6; THE NF-B SIGNALING SYSTEM AS AN INTEGRATOR OF DIVERSE SIGNALS;660 18.5.7; MATHEMATICAL MODELING OF THE TNF-a SIGNALING PATHWAY;660 18.5.8; DYNAMICS WITHIN THE CD95 DEATH-INDUCING SIGNALING COMPLEX DECIDE LIFE AND DEATH OF CELLS;661 18.5.9; TNF- SENSITIZES PRIMARY MOUSE HEPATOCYTES TO FAS/CD95-INDUCED APOPTOSIS: A SYSTEMS BIOLOGY APPROACH;662 18.5.10; UNIQUE PERSONALITIES WITHIN THE NF-B FAMILY: DISTINCT FUNCTIONS FOR P65 AND RELB IN THE OSTEOCLAST;662 18.5.11; THE INTERRELATIONSHIP BETWEEN NF-kappaB, Nrf2 AND KEAP1 IN CONTROLLING TNF INDUCED INFLAMMATORY RESPONSES;663 18.5.12; AATF IS A NOVEL ACTIVATOR OF THE C-JUN TRANSCRIPTION FACTOR UPON UV-LIGHT EXPOSURE;664 18.5.13; MICRORNA miR-146 IS A KEY REGULATOR OF AUTOIMMUNITY AND INFLAMMATION;665 18.5.14; MicroRNA-146a PROTECTS FROM TNF-INDUCED APOPTOSIS;666 18.5.15; miRNA REGULATION OF ENDOTHELIAL CELL RESPONSES TO TNF;666 18.6; ROLES OF THE TNF FAMILY
IN INFECTIOUS DISEASES AND INTERRELATIONSHIP OF THE TNF FAMILY AND PATTERN RECOGNITION RECEPTOR SIGNALING;667 18.6.1; THE IL-1 RECEPTOR / TOLL-LIKE RECEPTOR SUPERFAMILY: 10 YEARS OF PROGRESS;667 18.6.2; ACTIVATION OF INNATE IMMUNE REACTION BY MAMMALIAN DNA THAT ESCAPED FROM DEGRADATION, LEADING TO ANEMIA AND ARTHRITIS;668 18.6.3; MALARIAL HEMOZOIN IS A Nalp3 INFLAMMASOME ACTIVATING DANGER SIGNAL;669 18.6.4; CASPASE-8 REGULATES CELLULAR RESPONSE TO PATTERN RECOGNITION RECEPTORS;669 18.6.5; CELL-AUTONOMOUS ROLE OF TNFR AND TLR SIGNALING PATHWAYS IN ANTI-BACTERIAL IMMUNITY;670 18.6.6; BEYOND TNFR SIGNALING: THE MULTIFUNCTIONALITY OF TRADD;671 18.6.7; THE FUNCTION OF TRADD IN SIGNALING THROUGH TUMOR NECROSIS FACTOR RECEPTOR 1 AND TRIF-DEPENDENT TOLL-LIKE RECEPTORS;672 18.6.8; ROLE OF 4-1BB AND RELATED TNFR FAMILY MEMBERS IN CD8 T CELL RESPONSES TO VIRUSES;672 18.6.9; CRITICAL ROLE OF MEMBERS OF TNF OF MYCOBACTERIAL INFECTION REACTIVATION OF INFECTION BY TNF INHIBITORS;673 18.6.10; TUMOUR N ECROSI FACTOR ALPHA PRODUCED BY MACROPHAGES AND NEUTROPHILS IS REQUIRED FOR INITIAL PULMONARY PROTECTIVE INNATE IMMUNE RESPONSES BUT IS DISPENSABLE FOR PROTECTIVE IMMUNITY DURING PERSISTENT M. tuberculosis INFECTION;674 18.6.11; A CRITICAL ROLE OF THE POXVIRUS CrmD PROTEIN, A TNF AND CHEMOKINE BINDING PROTEIN, IN IMMUNE EVASION AND PATHOGENESIS;675 18.6.12; HEME SENSITIZATION TO TNF-MEDIATED PROGRAMMED CELL DEATH DICTATES THE OUTCOME OF PLASMODIUM INFECTION IN MICE;676 18.6.13; TNF/TNFR1 SIGNALING UP-REGULATES CCR5 EXPRESSION ON CD8+ T LYMPHOCYTES AND PROMOTES HEART TISSUE DAMAGE IN TRYPANOSOMA CRUZI INFECTION: BENEFICIAL EFFECTS OF TNF BLOCKADE;677 18.6.14; A LYMPHOTOXIN-DRIVEN PATHWAY TO HEPATOCELLULAR CARCINOMA;678 18.7; NOVEL ASPECTS OF IMMUNE REGULATION BY THE TNF FAMILY;678 18.7.1; TL1A (TNFSF15): A MASTER REGULATOR OF MUCOSAL INFLAMMATION;678 18.7.2; TL1A-DR3 INTERACTIONS IN T-CELL MEDIATED AUTOIMMUNITY;680 18.7.3; TNFR25/TL1A CONTROL CD4 REGULATORY CELLS, TH17/TH2 POLARIZATION
AND NKT-IL-13 ACTIVITY IMPORTANT IN MUCOSAL AND SYSTEMIC IMMUNITY;681 18.7.4; IDENTIFICATION OF NEW CANDIDATES AS MUCOSAL VACCINE ADJUVANT IN TNF SUPERFAMILY CYTOKINES;682 18.7.5; ROLE OF TWEAK/Fn14 PATHWAY IN INTESTINAL INFLAMMATION AND TISSUE REPAIR;683 18.7.6; TWEAK INDUCES PROLIFERATION IN RENAL TUBULAR EPITHELIUM: A ROLE IN RENAL HYPERPLASIA;684 18.7.7; THE EFFECTS OF TWEAK AND TNF ON HUMAN OSTEOBLASTS: MAPK DEPENDENT INDUCTION OF SCLEROSTIN EXPRESSION;685 18.7.8; TWEAK REGULATES PROINFLAMMATORY TNF RECEPTOR-1 SIGNALING;686 18.7.9; Fn14: A COMMON STRUCTURAL FRAMEWORK FOR SPECIES SEQUENCE DIVERGENCE;686 18.8; CONTROL OF LYMPHOCYTE FUNCTION AND REPERTOIRE BY THE TNF FAMILY;687 18.8.1; UNCONVENTIONAL LIGAND ACTIVATION OF HVEM MEDIATES CELL SURVIVAL;687 18.8.2; LYMPHOTOXIN-0 RECEPTOR SIGNALING LICENSES DENDRITIC CELLS TO PRIME CD8+ T CELL RESPONSES;688 18.8.3; THE TNF-FAMILY RECEPTORS RANK AND CD40 COOPERATIVELY REGULATE CENTRAL TOLERANCE IN THYMUS;688 18.8.4; THE DUAL ROLE OF TNF ON T CELL ACTIVATION;689 18.8.5; THE ROLE OF CD40 T CELLS IN AUTOIMMUNE DIABETES: THE IDENTIFICATION OF AUTOAGGRESSIVE T CELLS AND A MECHANISM TO THWART PERIPHERAL TOLERANCE;690 18.8.6; APRIL RESTORES B CELL SURVIVAL AND LPS ANTIBODY RESPONSE IN BTK-DEFICIENT MICE;691 18.8.7; REGULATION OF HEMATOPOIESIS BY CD137;692 18.8.8; THE LTR-PATHWAY PROMOTES B-CELL ACCUMULATION LARGELY VIA CXCL-13 EXPRESSION IN ECTOPIC LYMPHOID AGGREGATES IN NOD MOUSE LACRIMAL GLANDS;692 18.8.9; DIFFERENTIAL REQUIREMENT OF LTBR DURING THE MATURATION OF LYMPH NODE ANLAGEN STROMA;693 18.8.10; ANALYSIS OF B LYMPHOCYTE TUMOR NECROSIS FAMILY MEMBER SIGNALLING UTILIZING MEKK1KD TRANSGENIC MICE;694 18.9; NOVEL ASPECTS OF THE FUNCTIONS OF THE TRAFS AND CIAPS;694 18.9.1; PROTEIN UBIQUITINATION CASCADES AND SIGNALING BY TNF AND TOLL RECEPTORS;694 18.9.2; A SIGNALING PATHWAY FROM TNF RECEPTOR TO CELL DEATH;695 18.9.3; CRYSTAL STRUCTURE OF TRAF6 REVEALS SPECIFICITY AND MECHANISM OF TRAF6-MEDIATED UBIQUITINATION;696 18.9.4; TR
AF2 BALANCES THE LEVELS OF cIAP1 AND cIAP2 THEREBY PROTECTING CANCER CELLS FROM TNF INDUCED CELL DEATH;697 18.9.5; TUMOR NECROSIS FACTOR (TNF) RECEPTOR-ASSOCIATED FACTOR 1 (TRAF1) ENHANCES PROINFLAMMATORY TNF RECEPTOR-2 (TNFR2) SIGNALING AND MODIFIES TNFR1-TNFR2 COOPERATION;698 18.9.6; CELLULAR INHIBITORS OF APOPTOSIS (c-IAPs) ARE CRITICAL REGULATORS OF TNF FAMILY MEDIATED SIGNALING;699 18.9.7; THE cIAP1 AND cIAP2 INTERACTING DOMAIN OF TRAF2 IS IMPORTANT FOR TNF AND TWEAK INDUCED NF-B AND PROTECTION AGAINST TNF INDUCED APOPTOSIS;699 18.10; ADVANCES IN APPLYING OUR KNOWLEDGE TO THERAPY;700 18.10.1; AN UPDATE ON LESSONS LEARNED FROM ANTI-TNF THERAPY OF RHEUMATOID ARTHRITIS;700 18.10.2; BLOCKADE OF THE LYMPHOTOXIN-LIGHT PATHWAY AND THE TREATMENT OF AUTOIMMUNE DISEASE;701 18.10.3; EXPLORATION OF THE ROLES OF SOLUBLE AND TRANSMEMBRANE TNF IN ANIMAL MODELS OF INFLAMMATION AND IMMUNITY: COMPARATIVE STUDIES OF SELECTIVE INHIBITORS OF SOLUBLE TNF TO NONSELECTIVE ANTI-TNF BIOLOGICS;702 18.11; MECHANISMS OF PATHOLOGICAL THERAPEUTIC EFFECTSOF THE TNF FAMILY;703 18.11.1; TNF DRIVEN ACTIVATION OF INVARIANT NKT CELLS REGULATES COMBINED GUT AND JOINT INFLAMMATION;703 18.11.2; TNF PRIMING OF TYPE I IFN RESPONSES IN MONOCYTES AND MACROPHAGES;704 18.11.3; THE ANTI-TNF DRUG, INFLIXIMAB, HAS A PROINFLAMMATORY ACTION IN PATIENTS WITH TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME (TRAPS);705 18.11.4;SCIENCE OF TNF BLOCKADE IN VIVO;706 18.11.5; TNF-INDUCIBLE INHIBITOR I-KAPPAB EPSILON MODULATES IL-2 EXPRESSION IN T CELLS THROUGH REGULATION OF C-REL: IMPLICATIONS FOR CHRONIC INFLAMMATORY DISEASE;707 18.11.6; TUMOR NECROSIS FACTOR-A P75 RECEPTOR IS REQUIRED IN POST-MI RECOVERY IN ADULT HEART;708 18.11.7; TNF-ALPHA REGULATION OF CD38 EXPRESSION IN HUMAN AIRWAY SMOOTH MUSCLE: ROLE OF MAP KINASES AND NF-KAPPA B.;709 18.11.8; FUNCTIONAL CONSEQUENCES OF DISEASE-ASSOCIATED MUTATIONS IN TNFR1 ELUCIDATED BY TRANSCRIPTOME ANALYSIS;710 18.11.9; THE ROLE OF TNF SIGNALING IN SPONTANEOUS CO
LITIS DEVELOPMENT IN MICE LACKING NEMO SPECIFICALLY IN INTESTINAL EPITHELIAL CELLS;711 18.11.10; EFFECTS OF TNF- ON RENAL HEMODYNAMICS AND EXCRETORY FUNCTION IN MICE;712 18.11.11; LIPOPOLYSACCHARIDE PLUS GALACTOSAMINE-INDUCED FATAL HEPATITIS MEDIATED BY SECRETED TNF REQUIRES CASPASE-8 AND THE TWO BH3-ONLY PROTEINS BID AND BIM;713 18.11.12; STRATEGIES TO INHIBIT THE TOXICITY OF SYSTEMIC TNF TREATMENT WITH RETENTION OF ITS ANTITUMOR EFFECT;714 18.12; RATIONAL DESIGN OF NEW MEANS FOR THERAPEUTIC MODULATION OF FUNCTION OF THE TNF FAMILY;715 18.12.1; THE STALK REGION OF THE TNF RECEPTORS HIGHLY DETERMINES SOLUBLE TNF RESPONSIVENESS;715 18.12.2; THE EFFECT OF THERAPEUTIC ANTI-TNF AGENTS ON REVERSE SIGNALING VIA MEMBRANE TNF;716 18.12.3; DETERMINANTS FOR PRODOMAIN INHIBITION OF THE TNF- CONVERTING ENZYME (TACE) ZYMOGEN STATE;716 18.12.4; CREATION OF MUTANT LYMPHOTOXIN-ALPHAS WITH ENHANCED BIOACTIVITIES BY PHAGE DISPLAY TECHNIQUE;717 18.12.5; PHARMACOLOGICAL INHIBITION OF Tpl2 KINASE BLOCKS TNFalpha PRODUCTION IN HUMAN MONOCYTES AND MAY REPRESENT A NOVEL TREATMENT FOR RHEUMATOID ARTHRITIS;718 18.12.6; THE DISCOVERY OF A SERIES OF NOVEL SMALL MOLECULE MACROCYCLIC TNF ANTAGONISTS;719 18.12.7; BIOLOGICAL ACTIVITY OF ECTODYSPLASIN A IS CONDITIONED BY ITS COLLAGEN AND HEPARAN SULFATE PROTEOGLYCAN-BINDING DOMAINS;719 18.12.8; NOVEL MECHANISM OF ACTION FOR ANTI-LYMPHOTOXIN-ALPHA IN AUTOIMMUNE DISEASE: DEPLETION OF TH1 AND TH17 CELLS;720 18.12.9; THE DEVELOPMENT AND CHARACTERIZATION OF APRIL ANTAGONISTIC AGENTS;720 18.12.10; Fn14-TRAIL, A CHIMERIC INTERCELLULAR SIGNAL EXCHANGER, ATTENUATES EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;721 18.12.11; NOVEL TRAIL VARIANTS FOR TARGETED CANCER THERAPY;722 18.12.12; DESIGNED RECEPTOR SPECIFIC RHTRAIL VARIANTS ENHANCE INDUCTION OF APOPTOSIS IN CANCER CELLS;723 18.12.13; APOMAB, A FULLY HUMAN AGONISTIC DR5 MONOCLONAL ANTIBODY INHIBITS TUMOUR GROWTH AND OSTEOLYSIS IN MURINE MODELS OF BREAST CANCER DEVELOPMENT AND PROGRESSION;724 18.13; ROLES OF
THE TNF FAMILY IN NEURONAL DEVELOPMENT, FUNCTION PATHOLOGY;725 18.13.1; CENTRAL AND SYSTEMIC ACTION OF CYTOKINES IN NEURODEGENERATION;725 18.13.2; In vivo AND in vitro VALIDATION OF TNF AS A KEY NEUROINFLAMMATORY MEDIATOR OF NEUROTOXICITY AND NEURODEGENERATION IN MODELS OF PARKINSON'S DISEASE;726 18.13.3; THE CONTRIBUTION OF TNF TO SYNAPTIC PLASTICITY AND NERVOUS SYSTEM FUNCTION;727 18.13.4; AXONAL SELF-DESTRUCTION AND NEURODEGENERATIVE DISEASE;727 18.13.5; TNFalpha CHANGES DOWNSTREAM PATHWAYS OF NGF SIGNALLING FROM Erk1/2 TO Akt, WHICH BLOCKS NGF-DEPENDENT DIFFERENTIATION OF NEUROBLASTOMA CELLS;728 18.13.6; TNF RECEPTOR 2 SIGNALING: A TARGET FOR THERAPEUTIC INTERVENTIONS AGAINST NEURODEGENERATIVE DISEASES?;729 18.13.7; CASPASE 8 MEDIATES NEURON DEATH FOLLOWING in vivo AND in vitro EXCITOTOXIC INJURY;729 18.13.8; THE DEATH RECEPTOR ANTAGONIST C-FLIP IS NECESSARY FOR NEURONAL DIFFERENTIATION MEDIATED BY NEUROTROPHINS;730 18.13.9; NEURONAL NF-B (IKK) SUPPRESSES NEUROINFLAMMATION AND PROTECTS AGAINST NEUROLOGICAL DEFICITS IN DEMYELINATING CNS DISEASE;731 18.14; CELL DEATH MECHANISMS CONTROLLED BY THE TNF FAMILY;732 18.14.1; PROGRAMMED, ACCIDENTAL AND SECONDARY NECROSIS CONVERGE ON SIMILAR CELLULAR DISINTEGRATION FEATURES;732 18.14.2; RIBOFLAVIN KINASE COUPLES TNF RECEPTOR 1 TO NADPH OXIDASE AND APOPTOSIS;733 18.14.3; ATIA, A MULTI-TASK PROTEIN THAT PROTECTS CELLS AGAINST TNF-INDUCED APOPTOSIS;733 18.14.4; A RNA INTERFERENCE SCREEN IDENTIFIES NOVEL REGULATORS OF TNF-INDUCED PROGRAMMED NECROSIS;734 18.14.5; COMPARTMENTALIZATION OF TNF-R1 SIGNALING: CASPASE-8 AND CASPASE-7 SEQUENTIALLY MEDIATE ACTIVATION OF ACID SPINGOMYELINASE IN INTERNALIZED TNF-R1 RECEPTOSOMES;735 18.14.6; TNF RECEPTOR-1 (P55) AND DISC COMPONENTS TRANSLOCATE TO THE MITOCHONDRIA AND NUCLEUS IN TNF-TREATED HEPATOCYTES;735 18.14.7; FAS LIGAND SECRETION AND SELF-TOLERANCE IS REGULATED BY THE WISKOTT-ALDRICH SYNDROME PROTEIN;736 18.14.8; TNFR1 HAS AN EARLY UBIQUITINATION-DEPENDENT, NF-B-INDEPENDENT CELL DE
ATH CHECKPOINT;737 18.14.9; TNFa AND Fasl CYTOTOXICITY IS REGULATED BY THE EXTRACELLULAR MATRIX PROTEIN CCN1 in vitro AND in vivo;738 18.14.10; NON-CANONICAL NF-B SIGNALING PATHWAY IS REQUIRED FOR TNFA AUTOCRINE AND NECROSIS IN L929 CELLS;739 18.14.11; THE FORM OF FAS LIGAND DETERMINES WHETHER RETINAL GANGLION CELLS SURVIVE OR DIE DURING GLAUCOMA;740 18.14.12; FATAL LYMPHOPROLIFERATIVE DISEASE IN FASL- AND TRAIL DOUBLE-DEFICIENT MICE DUE TO FAILURE OF MATURE LYMPHOCYTE ACTIVATION-INDUCED CELL DEATH;741 18.14.13; DcR2 PROTECTS CANCER CELLS FROM TRAIL-INDUCED APOPTOSIS BY ACTIVATING Akt;742 18.14.14; ANALYSIS OF KNOCKOUT/ KNOCKIN MICE THAT EXPRESS A MUTANT FasL LACKING THE INTRACELLULAR DOMAIN;742 18.14.15; XIAP LOSS CONVERTS FAS-INDUCED APOPTOSIS SIGNALING IN HEPATOCYTES FROM TYPE II INTO TYPE I;743 18.14.16; c- FLIP PROTEINS AT THE NEXUS POINT OF FATE-DETERMINING SIGNALS ;743 18.15; Posters ROLES OF THE TNF FAMILY IN TISSUE HOMEOSTASIS AND NORMAL DEVELOPMENT;744 18.15.1; CHEMOKINES AS TARGETS OF EDA - A ROLE IN HAIR FOLLICLE DEVELOPMENT?;744 18.15.2; CASPASE-8 DEFICIENCY IN EPIDERMAL KERATINOCYTES TRIGGERS AN INFLAMMATORY SKIN DISEASE;745 18.16; ROLES OF THE TNF FAMILY IN CANCER;746 18.16.1; SUPPRESSION OF TUMOR GROWTH AND INTERRUPTION OF TUMOR ANGIOGENESIS BY SELECTIVE INHIBITION OF EITHER TNFR1/P55 OR TNFR2/75 IN MURINE MODEL OF LUNG CARCINOMA;746 18.16.2; INHIBITION OF TNFa/NIK/NF-kB TRANSDUCTION PATHWAY AS A POSSIBLE TARGET FOR PROSTATE CANCER TREATMENT;748 18.16.3; ERK and P38 PROMOTE SURVIVAL IN VITRO BY TNF-ALPHA STIMULATION IN PROSTATE CANCER;749 18.16.4; FUNCTION AND SIGNALING OF TRAIL IN PRIMARY HUMAN LEUKEMIA CELLS;750 18.16.5; STUDIES ON THE MECHANISM OF ACTION AND RESISTANCE TO TNFALPHA IN SOFT TISSUE SARCOMAS;750 18.16.6; LEUKOCYTE-DERIVED TNF- PROMOTES TUMOR GROWTH IN A SPONTANEOUS MODEL OF MAMMARY CARCINOGENESIS;751 18.16.7; ROLE OF B CELL IN TWO-STAGE SKIN CARCINOGENESIS;752 18.16.8; CO-EXPRESSION OF CD40L AND CD70 BY MELANOMA CELLS STIMULATES ANTI-
TUMOUR IMMUNE RESPONSE;753 18.17; NOVEL ASPECTS OF SIGNALING ACTIVATION BY THE TNF FAMILY;754 18.17.1; ESSENTIAL ROLE OF TNF-INDUCIBLE ZINC FINGER PROTEIN A20 ON THE DEATH RECEPTOR-MEDIATED APOPTOTIC CELL DEATH THROUGH THE BLUNTING JNK SIGNALLING;754 18.17.2; ADP-RIBOSYLATION OF HUMAN TNF-ALPHA BY ADP-RIBOSYLTRANSFERASE-1 (ART1);755 18.18; TRANSCRIPTIONAL NETWORKS AND SYSTEMS BIOLOGY;756 18.18.1; PKC- AKTS TOGETHER DURING TNF SIGNALLING;756 18.18.2; A PTP4A3 PEPTIDE PIMAP39 MODULATES TNF-alpha LEVELS AND ENDOTOXIC SHOCK;757 18.18.3; CROSS-TALK OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) AND HIF-1ALPHA PROTEIN AS ESSENTIAL PATHWAY FOR LIGAND-INDUCED TOLL-LIKE RECEPTOR 4-MEDIATED EXPRESSION OF PRO-INFLAMMATORY CYTOKINES;758 18.18.4; EXPRESSION OF TNFALPHA-ACTIVATED NFKAPPAB-DEPENDENT GENES IS AFFECTED BY HYPERTHERMIA AND ACTIVE HSF1;759 18.19; ROLES OF THE TNF FAMILY IN INFECTIOUS DISEASES AND INTERRELATIONSHIP OF THE TNF FAMILY AND PPR-SIGNALING;760 18.19.1; PHOSPHATASE PTP1B NEGATIVELY REGULATES MYD88- AND TRIF-DEPENDENT PROINFLAMMATORY CYTOKINE AND TYPE I INTERFERON PRODUCTION IN TLR-TRIGGERED MACROPHAGES;760 18.19.2; SHP-2 PHOSPHATASE DIFFERENTLY REGULATES MYD88- AND TRIF-DEPENDENT SIGNAL TRANSDUCTION IN LPS RESPONSE;761 18.19.3; CHARACTERISTICS AND FUNCTION OF ECTROMELIA GENE EVM008;761 18.19.4; IMPORTANCE OF TRAF1 SIGNALING DOWNSTREAM OF 4-1BB IN MEDIATING CD8 T CELL SURVIVAL;762 18.19.5; THE ROLE OF 4-1BBL IN RESCUING FUNCTIONALLY IMPAIRED HIV-SPECIFIC CD8 T CELLS;763 18.19.6; THE ROLE OF GITR IN CD8 T CELL RESPONSES TO INFLUENZA VIRUS;764 18.19.7; THE ROLE OF TRAF1 IN REGULATING TRAF2 STABILITY DOWNSTREAM OF 4-1BB SIGNALING;764 18.19.8; MOLECULAR CHARACTERIZATION OF CRMD, THE TNF AND CHEMOKINE DECOY RECEPTOR OF POXVIRUS;765 18.20; NOVEL ASPECTS OF IMMUNE REGULATION BY THE TNF FAMILY;766 18.20.1; STRUCTURAL AND FUNCTIONAL ANALYSIS OF DEATH RECEPTOR-6;766 18.20.2; CHARACTERIZATION OF DR6 SIGNALING. CELL SPECIFICITY IN APOPTOSIS INDUCTION AND NF- B ACTIVATION;
767 18.20.3; ESSENTIAL ROLE OF TNFRSF25/TL1A IN THE DEVELOPMENT OF ALLERGIC LUNG INFLAMMATION AND INFLAMMATORY BOWEL DISEASE;768 18.20.4; APRIL (TNFSF13), A SIGNIFICANT IMMUNE MODULATOR IN A MODEL OF RHEUMATOID ARTHRITIS, IN ALLERGIC LUNG INFLAMMATION AND IN ORAL/MUCOSAL IMMUNITY;768 18.21; CONTROL OF LYMPHOCYTE FUNCTION AND REPERTOIRE BY THE TNF FAMILY;769 18.21.1; ROLES OF NIK IN THYMIC EPITHELIAL CELLS FOR THE ESTABLISHMENT OF CENTRAL TOLERANCE;769 18.21.2; LYMHOTOXIN-B-RECEPTOR SIGNALING IS REQUIRED TO LICENSE DC FOR CROSS-PRIMING;770 18.21.3; LYMPHOID TISSUE INDUCER CELLS CONTROL CD8A- DENDRITIC CELL HOMEOSTASIS VIA THE LYMPHOTOXIN-BETA RECEPTOR PATHWAY;771 18.21.4; ROLE OF TNFRI AS A COSTIMULATORY MOLECULE DURING THE EARLY PHASE OF TCR STIMULATION IN CD3 T LYMPHOCYTES;772 18.21.5; LYMPHOTOXIN RECEPTOR SIGNALING SUPPORTS A UNIQUE STROMAL CELL NICHE THAT SUPPORTS IGA CLASS SWITCH RECOMBINATION IN THE INTESTINAL LAMINA PROPRIA;773 18.21.6; FUNCTIONAL CHARACTERIZATION OF CHIMERICAL RECEPTORS RANK-TNFR2 AND ANALYSIS OF THEIR INTERACTION WITH ADAPTOR PROTEINS TRAF;774 18.21.7; TNF RECEPTOR ASSOCIATED FACTOR 1 (TRAF1) MODIFIES CRYSTALLINE SILICA INDUCED LUNG INJURY;774 18.21.8; TRAF1 REGULATES TWEAK AND LTAB2-INDUCED NFKB SIGNALLING;775 18.22; MECHANISMS OF PATHOLOGICAL THERAPEUTIC EFFECTS OF THE TNF FAMILY;776 18.22.1; TRAIL INDUCED CELL DEATH IN COLON CARCINOMA CELLS IN VIVO AND IN VITRO: SENSITISATION BY ONCOGENES AND BY OTHER THERAPEUTICS;776 18.22.2; RELATION OF PRO-INFLAMMATORY AND ANTI-INFLAMMATORY CYTOKINES WITH MEDIATORS OF BONE REMODELATING SYSTEM IN PSORIATIC ARTHRITIS;777 18.22.3; THE REGULATION OF THE AMOUNT OF EXTRA CELLULAR DNA FIBRES BY THE TNF SUPER FAMILY;778 18.22.4; INDUCTION OF PRIMARY SCLEROSING CHOLANGITIS-LIKE DISEASE BY DR5-MEDIATED APOPTOSIS;779 18.22.5; LUPUS SERUM INDUCES SKIN INFLAMMATION THROUGH TNFR1 SIGNALING PATHWAY;780 18.22.6; CD8 T CELL-MEDIATED IMMUNE RESPONSES AGAINST CROSS-PRESENTING LIVER SINUSOIDAL ENDOTHELIAL CELLS LEADS TO H
EPATITIS;781 18.22.7; FUNCTIONAL CONSEQUENCES OF MUTATIONS IN TNFRSF1A, COMPARISON OF IN VITRO CELLULAR EVENTS TO FINDINGS FROM TISSUE SAMPLES ISOLATED FROM PATIENTS WITH TUMOUR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME (TRAPS);782 18.22.8; SIGNALING PATHWAYS OF MUTANT TUMOUR NECROSIS FACTOR RECEPTOR 1(TNFR1);783 18.22.9; EFFECT OF INFLIXIMAB TREATMENT ON CIRCULATING MONOCYTES IN RHEUMATOID ARTHRITIS PATIENTS: DIFFERENCES BETWEEN EARLY AND LATE DISEASE;783 18.22.10; APRIL EXPRESSION AND TARGETTING IN AUTOIMMUNE DISEASES;784 18.22.11; TNF SHEDDING AND EPIDERMAL INFLAMMATION IS CONTROLLED BY JUN/AP-1;785 18.22.12; DISTINCT CONTRIBUTIONS OF T CELL-DERIVED AND MACROPHAGE-DERIVED TNF IN PATHOGENESIS OF COLLAGEN INDUCED ARTHRITIS AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;786 18.22.13; HSP70 DEPENDENT ZINC PROTECTION AGAINST TNF-INDUCED LETHAL INFLAMMATION ALLOWS FOR A SAFER ANTITUMOR THERAPY;787 18.22.14; RESISTANCE OF SPRET/EI MICE TO TNF-INDUCED LETHAL SHOCK;787 18.22.15; ABLATION OF c-FLIP AUGMENTS CD95- AND GALACTOSAMINE/LPS-INDUCED LIVER INJURY THROUGH ACTIVATION OF c-JUN N-TERMINAL KINASE (JNK);788 18.23; RATIONAL DESIGN OF NEW MEANS FOR THERAPEUTIC MODULATION OF FUNCTION OF THE TNF;789 18.23.1; MODULATORY EFFECT OF SILIBININ ON THE CYTOKINE PRODUCTION AND FUNGICIDAL ACTIVITY OF HUMAN MONOCYTES INFECTED IN VITRO WITH PARACOCCIDIOIDES BRASILIENSIS;789 18.23.2; APOPTOSIS-INDUCING ACTIVITY OF SOLUBLE TRAIL EXPRESSED IN MESENCHYMAL STEM CELLS ON HUMAN CANCER CELLS;790 18.23.3; ANALYSIS OF LIGAND RECEPTOR INTERACTION WITH NEW SINGLE CHAIN TNF DERIVATIVES;791 18.23.4; DOMINANT NEGATIVE TNF PROTECTS FROM MYCOBACTERIUM BOVIS BCG AND ENDOTOXIN-INDUCED LIVER INJURY WITHOUT COMPROMISING HOST IMMUNITY TO MYCOBACTERIUM TUBERCULOSIS AND BCG INFECTIONS;792 18.23.5; THE TUMOR NECROSIS FACTOR-A CONVERTING ENZYME (TACE) IS REGULATED BY PHYSIOLOGICAL IONIC STRENGTH;793 18.23.6; ENHANCED ANTI-TUMOR EFFICACY OF A DR5-SPECIFIC TRAIL VARIANT OVER RHTRAIL IN A BIOLUMINESCEN
T OVARIAN CANCER XENOGRAFT MODEL;793 18.23.7; TARGET CELL-RESTRICTED STIMULATION OF THE CD95 (APO-1/FAS) DEATH RECEPTOR WITH VARIOUS BISPECIFIC CD20XCD95 ANTIBODIES;794 18.23.8; SENSITIZATION OF PROSTATE CANCER CELLS TO TRAIL-MEDIATED APOPTOSIS BY THE TUMOR-SUPPRESSING MATAIRESINOL LIGNAN;795 18.23.9; RECEPTOR ACTIVATION BY SOLUBLE OX40 LIGAND AND 41BB LIGAND IS ENHANCED BY OLIGOMERIZATION AND CELL SURFACE IMMOBILIZATION;796 18.23.10; RELEVANCE OF OLIGOMERIZATION AND CELL SURFACE IMMOBILIZATION FOR THE ACTIVITY OF SOLUBLE VARIANTS OF CD27L AND GITRL;797 18.23.11; TRAIL FUSED TO SURFACTANT PROTEIN-D AND COLLECTIN-11 AS MODEL FOR TNF-SF COLLECTIN FUSION PROTEINS;797 18.23.12; MUTANT TNF ELICITS MUCOSAL AND SYSTEMIC IMMUNITY AGAINST HIV-1 AND INFLUENZA VIRUS;798 18.23.13; DEVELOPMENT OF A NOVEL METHOD USING PHAGE DISPLAY, GENE SHUFFLING AND IMPROVED RECEPTOR SELECTIVITY TO PRODUCE MUTANT TNFS;799 18.23.14; ANTI-INFLAMMATORY EFFECTS OF A NOVEL TNFR1-SELECTIVE ANTAGONISTIC TNF MUTANT ON ESTABLISHED MURINE COLLAGEN-INDUCED ARTHRITIS;800 18.23.15; RECEPTOR INTERACTION OF TUMOR NECROSIS FACTOR (TNF) BASED ON 3D STRUCTURAL ANALYSIS OF A FULLY ACTIVE TNFR1-SELECTIVE TNF MUTANT;801 18.23.16; THE DEVELOPMENT OF FULLY ACTIVE RECEPTOR-SELECTIVE TUMOR NECROSIS FACTOR (TNF) MUTANTS;802 18.23.17; THE ROLE OF HEPARAN SULFATE PROTEOGYCANS IN APRIL SIGNALLING;803 18.23.18; ENHANCEMENT OF ANTITUMOR PROPERTIES OF RHTRAIL BY AFFINITY INCREASE TOWARD ITS DEATH RECEPTORS;804 18.23.19; IMPROVED TUMOR CELL KILLING BY TRAIL REQUIRES SELECTIVE AND HIGH AFFINITY RECEPTOR ACTIVATION;805 18.23.20; COMPUTATIONAL DESIGN OF RECEPTOR SELECTIVE TRAIL VARIANTS;806 18.23.21; EFFICACY OF ANTI-TNF-A ANTIBODIES IN INTESTINAL CELL LINES SYSTEM;807 18.24; ROLES OF THE TNF FAMILY IN NEURONAL DEVELOPMENT, FUNCTION PATHOLOGY;808 18.24.1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND-RELATED SIGNAL TRANSDUCTION IN NEURODEGENERATIVE PROCESSES;808 18.24.2; APOPTOSIS REGULATION IN NEUROSECRETORY CELLS OF H
YPOTHALAMUS OF AGED TNF-KNOCKOUT MICE;809 18.25; CELL DEATH MECHANISMS CONTROLLED BY THE TNF FAMILY;809 18.25.1; ASSOCIATION OF FASL AND CAVEOLIN-1 IN LIPID RAFTS IS ESSENTIAL FOR THE ONSET OF FASL-MEDIATED CELL DEATH;809 18.25.2; TNF ALPHA INDUCE SHEDDING OF CD30 AND CD45 AND LDH RELEASE FROM K-562 CELLS;810 18.25.3; DIFFERENTIAL ROLE OF FLIP ISOFORMS IN TNF-INDUCED CELL LIFE AND DEATH RESPONSES;811 18.25.4; DEATH WITHOUT LIGANDS: NOVEL APPROACH IN INDUCTION OF TNF RECEPTOR SUPERFAMILY MEDIATED CELL DEATH;811 18.25.5; INVOLVEMENT OF ENDOCYTOSIS IN TRAIL-R1/DR4 AND TRAIL-R2/DR5 TRAFFICKING AND SIGNALING;812 18.25.6; GENERATION OF LMP1-TR1/2 FUSION PROTEINS AND RECOMBINANT TRAIL;813 18.25.7; ENHANCED CASPASE-8 ACTIVATION WITHIN THE DISC PRIMES OVER THE MITOCHONDRIAL PATHWAY TO SENSITIZE DCR2 EXPRESSING CELLS TO TRAIL INDUCED CELL DEATH AFTER CHEMOTHERAPY;814 18.25.8; INHIBITION OF CASPASES ENHANCES THE CYTOTOXIC EFFECT OF TNF IN HUMAN MYELOMONOCYTIC U937 CELL LINE;814 18.25.9; ANCHORAGE DEPENDENCY OF TNF AND CD40 LIGAND-INDUCED MAPK SIGNALLING;815 18.25.10; LIFEGUARD DIRECTLY INTERACTS WITH NEUROBLASTOMA-DERIVED SULFHYDRYL OXIDASE;816 18.25.11; MEMBRANE FAS LIGAND CLEARS BACTERIA AND SOLUBLE FAS LIGAND PROTECTS HOST TISSUE DURING S. AUREUS INDUCED ENDOPHTHALMITIS;817 18.25.12; TRAIL RESISTANCE IN NON-TRANSFORMED CELLS IS PROVIDED BY MULTIPLE FACTORS;818 18.25.13; DOWNREGULATION OF C-FLIP PROMOTES CASPASE-DEPENDENT JNK ACTIVATION AND REACTIVE OXYGEN SPECIES ACCUMULATION IN TUMOR CELLS;819 18.25.14; SEVERAL MECHANISMS FOR THE REGULATION OF HUMAN T CELL BLAST ACTIVATION BY FASL AND APO2L/TRAIL;819 18.25.15; TNFALPHA-INDUCED ACTIVATION OF NFKAPPAB PROTECTS AGAINST UV-INDUCED APOPTOSIS SPECIFICALLY IN P53-PROFICIENT CELLS;820 18.25.16; INFLUENCE OF OPTINEURIN ON ADENOVIRUS E3-14.7K MEDIATED TNF-RESISTANCE;821 18.25.17; CD137-INDUCED CELL DEATH IN PERIPHERAL BLOOD MONONUCLEAR CELLS;822 18.25.18; REGULATION OF CELL DEATH BY c-FLIP PHOSPHORYLATION;822 18.25.19; MATHEMATICAL
MODELING OF APOPTOSIS AS A FUNCTION OF C-FLIP TURNOVER AND AT RANDOM PARAMETER DISTRIBUTIONS;823 18.25.20; RIP1, A JACK-OF-ALL-TRADES;824 19;Subject Index;825
